What is the likelihood of metastasis in squamous cell carcinoma?

Metastatic Risk of Squamous Cell Carcinoma

The overall metastatic rate of cutaneous squamous cell carcinoma (cSCC) is approximately 2-4%, while head and neck squamous cell carcinoma (HNSCC) presents with significantly higher rates of regional and distant spread at diagnosis. 1

Cutaneous SCC Metastatic Rates

The metastatic potential of cSCC varies based on multiple factors:

Overall Population Risk

• The baseline metastatic rate for cSCC is approximately 4% in the general population 1
• More recent large cohort studies report rates between 1.9-2.6% over extended follow-up periods 2
• Another comprehensive study found a mean annual metastatic rate of 2.28% 3
• The reported range in literature spans 1.2-5%, reflecting variations in study populations and follow-up duration 4

High-Risk Populations

Immunosuppressed patients face substantially elevated risk:

• Solid organ transplant recipients (SOTRs) have 2-3 times higher metastatic risk compared to immunocompetent patients 1
• These patients require dose reduction of immunosuppressive agents when feasible, particularly minimizing calcineurin inhibitors in favor of mTOR inhibitors 1

Temporal Pattern of Metastasis

• Nearly half (49.4%) of metastases are detected within 6 months of primary cSCC diagnosis 3
• The majority (84.7%) of patients with metastatic cSCC had no prior history of cSCC 3

Independent Risk Factors for Metastasis

The following factors independently predict metastatic potential and should guide risk stratification:

Tumor Size

• Diameter ≥2 cm carries a 7-fold increased risk of nodal metastasis (subhazard ratio 7.0) and 15.9-fold increased risk of disease-specific death 5
• Tumors 20-29.9 mm also demonstrate significantly elevated metastatic risk 3

Depth of Invasion

• Invasion beyond subcutaneous fat increases metastatic risk 9.3-fold and disease-specific death 13-fold 5
• Clark's level 5 invasion is an independent predictor of metastasis 3

Histologic Differentiation

• Poor differentiation increases nodal metastasis risk 6.1-fold and disease-specific death 6.7-fold 5
• This remains significant across multiple large cohort studies 2

Perineural Invasion (PNI)

• PNI confers a 5.3-fold increased hazard for metastasis 2
• Associated with 3.6-fold increased disease-specific death 5

Anatomic Location

High-risk sites include:

• Lower lip: 4.84-fold increased metastatic risk 3, 2
• Ear and retro-auricular area: 3.31-fold increased risk 2
• Temple: 5.9-fold increased disease-specific death 5
• Forehead: significantly elevated metastatic potential 3
• Cheek: 3.18-fold increased risk 2
• Anogenital location: associated with poor outcomes, though less common 5

Age Factors

• Patients <50 years or 70-79 years demonstrate increased metastatic risk 3

Protective Factors

Certain clinical features correlate with reduced metastatic risk:

• Use of isosorbide mono-/di-nitrate and/or aspirin 3
• Comorbid actinic keratosis or basal cell carcinoma 3
• Actinic keratosis or cSCC in situ preceding primary cSCC 3

Metastatic Pattern and Prognosis

Pattern of Spread

• Cutaneous in-transit and regional lymph node metastases are most common, followed by distant metastases 1
• In extremity cSCC, regional lymph nodes are involved in nearly all metastatic cases 6

Survival Outcomes

• Disease-specific death occurs in approximately 2.1% of cSCC patients 5
• Five-year survival with nodal metastasis is only 39% despite aggressive therapy 6
• Extracapsular nodal extension carries grave prognostic significance 6
• ≥3 nodal metastases and extranodal extension significantly predict poor prognosis in metastatic disease 3

Head and Neck SCC Considerations

For HNSCC (oral cavity, larynx, oropharynx, hypopharynx):

• Chest imaging is mandatory for high-risk tumors (presence of neck adenopathies) to assess distant metastases 1
• FDG-PET combined with contrast-enhanced CT has higher sensitivity than either modality alone for detecting metastases 1
• HPV-positive oropharyngeal SCC has distinct prognostic implications compared to other head and neck sites 1

Clinical Implications

Given these metastatic rates and risk factors, the following approach is warranted:

• Patients with ≥2 high-risk features require thorough regional lymph node examination 1
• Imaging for nodal assessment (CT, PET/CT, or ultrasound) should be considered for tumors with BWH category ≥T2b 1
• Multidisciplinary consultation is essential for all metastatic cSCC cases 1
• Close surveillance is critical, as local treatment failures increase metastatic risk 6